Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Praecis Pharmaceuticals Inc
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Praecis Pharmaceuticals Inc since year 2005.
Table 2 shows the detailed insider transactions of Praecis Pharmaceuticals Inc since 2005.
The reporting company's ticker symbol is PRCS. The reporting company's CIK number is 1033025.
The total value of stock buying since 2005 is $22,125.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $167,846.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2006-09-01||Mclaughlin Kevin F (President and CEO)||Option Ex||24,200||1.33||32,186|
|2006-07-10||Gefter Malcolm L Phd (Chairman and CSO)||Option Ex||92,500||1.33||123,025|
|2006-03-13||Gefter Malcolm L Phd (Director)||Option Ex||9,500||1.33||12,635|
|2005-03-07||Keavany Michael J (Marketing)||Buy||15,000||1.48||22,125|
Insider trading activities including stock purchases, stock sales, and option exercises of PRCS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Praecis Pharmaceuticals Inc (symbol PRCS, CIK number 1033025) see the Securities and Exchange Commission (SEC) website.